The Accreditation Subcommittee of the EBMT regularly publishes special reports 
on current practice of haemopoietic stem cell transplantation for haematological 
diseases, solid tumours and immune disorders in Europe. Major changes have 
occurred since the first report was published in 1996. Haemopoietic stem cell 
transplantation today includes grafting with allogeneic and autologous stem 
cells derived from bone marrow, peripheral blood and cord blood. With reduced 
intensity conditioning regimens in allogeneic transplantation, the age limit has 
increased, permitting the inclusion of older patients. New indications have 
emerged such as autoimmune disorders and AL amyloidosis for autologous, and 
solid tumours for allogeneic transplants. The introduction of alternative 
therapies has challenged well-established indications such as imatinib for 
chronic myeloid leukaemia. An updated report with revised tables and operating 
definitions is presented here.